Korro Bio, Inc.
H.C. Wainwright reiterated a Buy rating and $15.00 price target for Korro Bio (KRRO) after the company dosed the first cohort in its Phase 1/2 trial for KRRO-121. The stock is down 77% over the past year, trading at $9.97. Korro Bio has a strong current ratio of 9.55 and more cash than debt. The ANCHOR trial is expected to take about a year, with primary completion estimated for the second half of 2027.
Korro Bio (KRRO) has dosed the first cohort in its Phase 1/2 trial for KRRO-121, an RNA-editing treatment for hyperammonemia. The trial, conducted in Australia, includes healthy volunteers and plans to dose Urea Cycle Disorder patients in early 2027, with interim results expected later that year.
Korro Bio (KRRO) dosed the first cohort in its Phase 1/2 trial for KRRO-121, a treatment for hyperammonemia in UCD patients and hepatic encephalopathy. The trial will assess safety and efficacy, with patient dosing expected in 2027. KRRO-121 uses the company's OPERA platform to edit RNA.
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning KRRO (Korro Bio, Inc.). Coverage has skewed bullish: 4 bullish, 2 neutral, and 0 bearish.
Recent KRRO coverage spans insider activity, financial news and technology.
In the last 30 days, KRRO insiders filed 6 SEC Form 4 transactions — no purchases and 6 sales ($686K). The most active reporter was FORMELA JEAN FRANCOIS with 4 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The start of the Phase 1/2 trial provides a concrete catalyst that could lift the stock if safety data are positive.
First‑in‑human dosing is a material milestone that may lift the stock on positive safety/PK data.
Initial dosing may lift sentiment but impact depends on safety data; short‑term price likely neutral.
Insider sell may signal lack of confidence, but size is modest.
The insider sell represents a modest $399K divestment, likely exerting slight downward pressure on KRRO.
AlphAI scores every news story that mentions KRRO with an AI model for sentiment and relevance, and aggregates insider trades from Korro Bio, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
H.C. Wainwright reiterated a Buy rating and $15.00 price target for Korro Bio (KRRO) after the company dosed the first cohort in its Phase 1/2 trial for KRRO-121. The stock is down 77% over the past year, trading at $9.97. Korro Bio has a strong current ratio of 9.55 and more cash than debt. The ANCHOR trial is expected to take about a year, with primary completion estimated for the second half of 2027.
2 min readKorro Bio (KRRO) has dosed the first cohort in its Phase 1/2 trial for KRRO-121, an RNA-editing treatment for hyperammonemia. The trial, conducted in Australia, includes healthy volunteers and plans to dose Urea Cycle Disorder patients in early 2027, with interim results expected later that year.
1 min readKorro Bio (KRRO) dosed the first cohort in its Phase 1/2 trial for KRRO-121, a treatment for hyperammonemia in UCD patients and hepatic encephalopathy. The trial will assess safety and efficacy, with patient dosing expected in 2027. KRRO-121 uses the company's OPERA platform to edit RNA.
2 min readFORMELA JEAN FRANCOIS sold 48,690 indirectly-held shares of Korro Bio, Inc. (KRRO) at an average of $14.09 ($13.99–$14.12, $0.69M total) across 4 trades over 2026-09-11 to 2026-09-14 under a Rule 10b5-1 trading plan.
1 min readKorro Bio (KRRO) director Jean Francois Formela reported indirect sales of 28,468 shares of common stock on August 19, 2026, by associated venture funds. The sales, totaling $399K, were made under a Rule 10b5-1 trading plan at a weighted average price of $14.00 per share. Formela disclaims beneficial ownership except for any pecuniary interest.
1 min readLynx1 Capital Management LP purchased 6,684 indirectly-held shares of Korro Bio, Inc. (KRRO) at an average of $11.79 ($11.40–$13.19) across 2 trades over 2026-08-06 to 2026-08-10.
2 min readKorro Bio, Inc. (KRRO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update — KRRO-121, a potential first-in-class transformational treatment for hyperammonemia, remains on track to commence first-in-human clinical trial in second half of 2026 — Received Orphan
6 min readKorro Bio (Nasdaq: KRRO) said it granted non-statutory stock options to seven newly hired employees under its 2026 Inducement Plan. Four employees received options for 6,000 shares total at $10.59 per share (June 10, 2026 close), and three received options for 17,000 shares total at $14.72 (July 8, 2026 close). Options vest over four years.
2 min readFORMELA JEAN FRANCOIS sold 110,023 indirectly-held shares of Korro Bio, Inc. (KRRO) at an average of $14.02 ($13.96–$14.03, $1.54M total) across 4 trades over 2026-07-02 to 2026-07-06 under a Rule 10b5-1 trading plan.
2 min readFORMELA JEAN FRANCOIS sold 171,405 indirectly-held shares of Korro Bio, Inc. (KRRO) at an average of $14.34 ($13.95–$14.98, $2.46M total) across 8 trades over 2026-06-22 to 2026-06-24 under a Rule 10b5-1 trading plan.
2 min read
